

D4

D4 DATA- DRIVEN DRUG DEVELOPMENT

Hyperion Hotel
Basel, Switzerland
2nd – 3rd October 2019

Gather Data, Evidence and Case Studies to Transform Data-Driven Drug Development

www.d4-europe.com

Attending Organisations



D4 Europe is ram packed full of case studies – opportunities to get into the weeds, learn and be inspired. Broken down into two sections ('Enabling Science' and 'Doing Science'), every session has been carefully screened to ensure that data and evidence is presented to back up the incredible work that's being pioneered within pharma companies. This is a deep-learning environment.

Why is that important?

It's time to move beyond the vision and into reality. Pharma productivity is under pressure, as are senior people in pharma. We need results now – not in 10 years' time. The technology is finally available to make huge strides – not just incremental ones – that will make a huge difference to the bottom line. But most importantly, patients are waiting.

Want to get things done? Smaller is better...

The format is simple. 100 senior technical and scientific leaders in the same room. This is designed to ensure that you leave the event not just armed with new knowledge, but with a renewed list of contacts who you've actually had the time to spend time getting to know. Don't commit to a 1000 person meeting where you learn nothing and get face-time with no-one for longer than two minutes. D4 Pharma is a harbour from the storm, where you can spend two highly; productive days in a friendly, welcoming environment where you will meet the right people and develop the right relationships to move your biodata capabilities forward.

"A GREAT BLEND OF TOPICS AROUND DATA-DRIVEN DRUG DISCOVERY BRINGING PEOPLE FROM DIFFERENT DOMAINS CLOSE TO EACH OTHER."

Martin Romacker, Principal Scientist, Roche

"A GREAT OPPORTUNITY TO GET INSIDE THE MINDS OF LEADING THINKERS IN LEVERAGING DATA SCIENCE AND IT TO CREATE NEW DRUGS."

Steve Hoang, Head of Computational Biology, Hemoshear Therapeutics


Key Benefits of Attending:



Learn and get inspired from listening to 20+ case studies presenting data, evidence, lessons learned, mistakes and insights that will drive your own biodata capabilities forward



Understand and leverage the fast emerging role of the healthcare data ecosystem in transforming drug discovery and development



Build your biodata capabilities from the bottom up, from both a technical and scientific standpoint.



Get straight past the hype and vision and into the detail on AI/ML as a tool to build, manage and examine knowledge and vast data sets



Spend quality time with other senior-level practitioners from Europe's leading pharma organizations, and leave armed with not just new ideas, but a new support network

Speakers



George Papadatos
Director of Discovery
Data Strategy, R&D
GSK



Emma Laing
Lead Bioinformatician
in Neuroscience and
Principal Research
Scientist
Eli Lilly



Philipp Diesinger
Global Chief Data
Scientist
**Boehringer
Ingelheim**



Philippe Marc
Director, Global
Head of Integrated
Data Science
Novartis



Gisbert Schneider
Professor of
Computer-Assisted
Drug Design
ETH Zurich



Paul Agapow
Director, Health
Informatics
AstraZeneca



Peter Speyer
Global Head of
Digital, Medical
and RWE Solutions
Novartis



Olivier Leconte
Global Head
of Statistical
Programming &
Analysis
Janssen



James Dunbar
Senior Bioinformatics
Data Scientist
BenevolentAI



Victor Neduva
Programme Lead, Merck
Research Labs UK
Merck



**Abel Archundia
Pineda**
Global Head of IT, BP
Bayer



Xosé Fernández
Chief Data Officer
Institut Curie



Martin Akerman
Co-Founder & Chief
Technology Officer
Envisagenics



Etzard Stolte
Global Head,
Knowledge
Management,
Pharma Technical
Development
Roche




Craig Fox
Chief Scientific
Officer
C4X Discovery





Pedro Ballester
Group Leader,
Machine Learning for
Precision Oncology
and Drug Design
INSERM




Martin Romacker
Principal Scientist, pREDi,
Data Information Architecture
in Technical Solution Delivery,
Roche Pharma Research and
Early Development
Roche



Pierre Farmer
Head of Data Science
Technology, Chemical
Biology & Therapeutics
(CBT) Department
Novartis



Ramon Hernandez Vecino
Head of Real World
Evidence Data & Analytics
Engagement Lead R&D
Sanofi





D4 DATA-DRIVEN DRUG DEVELOPMENT

Hyperion Hotel
Basel, Switzerland
2nd – 3rd October 2019



Day 1 | Enabling Science

8.00 Registration and coffee

9.00 Opening Address from the Chairperson
Xosé Fernández, Chief Data Officer, *Institut Curie*

SETTING THE SCENE: WHY LEVERAGING BIODATA IS SO IMPORTANT, AND HOW TO DO IT

9.10 **KEYNOTE:** Pharma R&D Data Integration – Data Landscaping, FAIR Play, FAIRification, Killer Apps and the ROI Question

Philippe Marc, Director, Global Head of Integrated Data Science, *Novartis*

9.50 **KEYNOTE:** The Big Picture: Why Getting Data Right is so Important for Pharma

Martin Romacker, Principal Scientist, *Roche*

10.20 Speed Networking

Meet other conference attendees in a fun session designed to break the ice and help you identify who you would most like to speak with later in the meeting. Bring plenty of business cards!

11.10 Morning break and coffee

BIODATA INTEGRATION AND STRATEGIC CONSIDERATIONS

11.30 **CASE STUDY:** Transforming Data into Knowledge for R&D and Beyond (for Market Access and Convincing Payors) in the Most Efficient Ways.

Anne Danniau, Head of Data Sciences, *Grunenthal Group*

12.00 **CASE STUDIES:** Harnessing the Complexity of Cancer to Drive New Insights and Treatments

Xosé Fernández, Chief Data Officer, *Institut Curie*

12.30 **PANEL DISCUSSION:** Building and Making the Business Case for Investment and Executive Attention/Focus on Better Data-Processes and Infrastructure.

Anne Danniau, Head of Data Sciences, *Grunenthal Group*
Philippe Marc, Director, Global Head of Integrated Data Science, *Novartis*
Martin Romacker, Principal Scientist, *Roche*
Abel Archundia Pineda, Global Head of IT, BP, *Bayer*

13.00 Lunch

STRENGTHENING BIODATA UTILITY AND DATA SCIENCE CAPABILITIES

14.00 **KEYNOTE:** Data-Driven Scientific Problem-Solving in Drug R&D: Developing Data Science Capabilities in a Forward-thinking Global Pharmaceutical Company

Philipp Diesinger, Global Chief Data Scientist, *Boehringer Ingelheim*

14.30 **CASE STUDY:** Lessons Learned from Implementing Automated Knowledge Management Methods

Knowledge extraction methods are notoriously difficult, but hold great promise if the quality is sufficient. Using various Machine Learning methods over the last 5 years, Knowledge Management at Roche has been able to pass the necessary threshold of around 75% accuracy.

Etzard Stolte, Global Head, Knowledge Management, Pharma Technical Development, *Roche*

15.00 Afternoon break and coffee

DRIVING BIOPHARMA R&D PRODUCTIVITY

15.30 **What to do About FAIR?**

Andrea Splendiani, Director, Data Strategy, *Novartis*

INNOVATION SHOWCASE

16.00 **INNOVATION SHOWCASE:** 4 x 10 minute presentations.

This is an interactive session presenting the most innovative breakthrough technologies affecting data-driven drug development today (not tomorrow). At the end of the session, the audience vote for the technology/presentation that they think will have the greatest impact.

EXAMINING THE FUTURE OF PHARMA

16.45 **PANEL DISCUSSION:** "How would you build a pharma company from scratch, five years from now? What would be the difference, from talent to drug discovery to commercialization?"
Bertrand Bodson, Chief Digital Officer, *Novartis*.

This panel will seek to provide enlightenment on that important question.

Paul Agapow, Director, Health Informatics, *AstraZeneca*
Philipp Diesinger, Global Chief Data Scientist, *Boehringer Ingelheim*

Martin Akerman, Co-Founder & Chief Technology Officer, *Envisagenics*

Victor Neduva, Programme Lead, Merck Research Labs UK, *Merck*

17.30 **Chairperson's Closing Remarks**

Xosé Fernández, Chief Data Officer, *Institut Curie*

18.05 **Drinks Reception**

A chance to relax, unwind and continue chatting to other conference attendees over a glass of wine, beer or soft drink.

19.15 **Optional Dinner**

A relaxed, informal meal at a local restaurant. Sign-up on the day. The meal is not included in your ticket price.



D4 DATA-DRIVEN DRUG DEVELOPMENT

Hyperion Hotel
Basel, Switzerland
2nd – 3rd October 2019

Day 2 | Doing Science

8.00 Registration and coffee

9.00 Opening Address from the Chairperson

Emma Laing, Lead Bioinformatician in Neuroscience and Principal Research Scientist, **Eli Lilly**

PATIENTS AND LEVERAGING THE HEALTH DATA ECOSYSTEM

9.05 **KEYNOTE: The (R)evolution of the Health Data Ecosystem and the Role of the Patient**

Peter Speyer, Global Head of Digital, Medical and Real-World Data Solutions, **Novartis**

9.35 **CASE STUDIES: Filling the Gaps in Translational Research**

Paul Agapow, Director, Health Informatics, **AstraZeneca**

DATA-DRIVEN INNOVATIONS IN TARGET ID AND VALIDATION

10.05 **CASE STUDIES: Genetics and -omics Data Driven Target Discovery/Validation**

Emma Laing, Lead Bioinformatician in Neuroscience and Principal Research Scientist, **Eli Lilly**

10.35 Morning break and coffee

11.05 **CASE STUDY: Artificial Intelligence-enabled Target Identification**

James Dunbar, Senior Bioinformatics Data Scientist, **BenevolentAI**

11.35 **CASE STUDY: C4X Discovery's Novel Target Identification Platform Taxonomy3® and its Utility in Neurodegenerative and Autoimmune Disorders**

Craig Fox, Chief Scientific Officer, **C4X Discovery**

12.05 **CASE STUDY: Drug Target Discovery with Splicing AI**

Martin Akerman, Co-Founder & Chief Technology Officer, **Envisagenics**

12.35 Lunch

DATA-DRIVEN INNOVATIONS IN DRUG DISCOVERY

13.25 **Opening Comments from the Chairperson**

Pedro Ballester, Group Leader, Machine Learning for Precision Oncology and Drug Design, **INSERM**

13.30 **CASE STUDY: From (Big) Data to Value in Drug Discovery: Surfing on the Data Lake**

George Papadatos, Director of Discovery Data Strategy, R&D, **GSK**

14.00 **CASE STUDY: Accelerating the Drug Discovery Process Using Advance Analytics. How AI and Advance Analytics Contribute to the Discovery of New Lead Compound**

Pierre Farmer, Head of Data Science Technology, Chemical Biology & Therapeutics (CBT) Department, **Novartis**

AI-LED DRUG DESIGN

14.30 **Rethinking Drug Design - The Impact of Artificial Intelligence**

Gisbert Schneider, Professor of Computer-Assisted Drug Design, **ETH Zurich**

15.00 Afternoon break and coffee

AI-DRIVEN INSIGHTS FROM THE CLINIC

15.30 **CASE STUDY: Exploiting Artificial Neural Networks (ANNs) to Gain Clinically Actionable Insights into Mechanisms of Drug Combination Action**

Jonathan Wagg, Head of Oncology Disease Modelling, **Roche**

16.00 **CASE STUDY: Predicting Patient Response - Machine Learning for Precision Oncology**

Cancer patients often respond differently to the same drug treatment. Precision oncology aims at predicting which treatments will be effective on a given patient. Integrated treatment response and tumour molecular data from patients can be exploited by Machine Learning (ML) techniques to build multi-variate models able to predict treatment response.

Pedro Ballester, Group Leader, Machine Learning for Precision Oncology and Drug Design, **INSERM**

WHAT NEXT FOR BIOPHARMA?

16.30 **PANEL DISCUSSION: How Did We Get Here, Where Do We Go Now?**

Emma Laing, Lead Bioinformatician in Neuroscience and Principal Research Scientist, **Eli Lilly**

George Papadatos, Director of Discovery Data Strategy, R&D, **GSK**

Olivier Leconte, Global Head of Statistical Programming & Analysis, **Janssen**

Peter Speyer, Global Head of Digital, Medical and Real-World Data Solutions, **Novartis**

17.15 **Chairperson's Closing Remarks and Close of Conference**

D4

D4 DATA-DRIVEN DRUG DEVELOPMENT

Basel, Switzerland
2nd – 3rd October 2019
www.d4-europe.com

Innovating the Use of Biodata to Drive Value in Pharma R&D

Senior people in pharma told us:

1. Existing meetings do not adequately cater for the people who are driving the change and investment in R&D IT in pharma
2. Those meetings are extremely light on evidence and supporting data within use-cases.
3. Those meetings focus on **future possibilities**, but not on how current advances in data-driven approaches can create value and ROI **today**.

That's where D4 – EUROPE comes in

This meeting is designed specifically to cater for senior people in pharma, combining (1) strategic insights of value to IT/R&D leaders, with (2) technical, evidence-based use-cases and data that attendees can take away to (3) move forwards with confidence and achieve real development in their organizations today and beyond.

The story so far...

We ran this meeting in Boston in March, to much acclaim.

92%

Of end-user attendees were senior.
E.g. C-level, Director, VP, Head.

85%

Of end-user attendees were from pharma companies. The others were mostly academia (e.g. Stanford, Harvard) or the FDA.

95%

Of attendees would strongly recommend this meeting to a colleague or friend in industry.

107

Registrants in total, exceeding our goal of 100 senior-level attendees to create the right environment for exchange of ideas and networking.

Attendees included senior people in IT and R&D from **AbbVie, AstraZeneca, Alexion, Biogen, Celgene, Eisai, GSK, Janssen, Merck, Pfizer, Regeneron, Roche, Sanofi, Takeda** and a host of mid-sized and emerging pharma.

For the full list, please contact Denvor Oorloff, Commercial Manager, T: +44 (0) 208 191 8810 E: denvor@frontlinegenomics.com



**D4 DATA-
DRIVEN DRUG
DEVELOPMENT**

Basel, Switzerland
2nd – 3rd October 2019
www.d4-europe.com



Sponsorship Packages

	Keynote Presentation	Agenda Presentation	Panel Speaking Slot	Interview	Email Blast	Post Event Report Editorial	Post Event Report Advert	Booth	Attendee List With Contact Details*	Staff Passes	Client Passes	Branding
Headline Partner £30,000	✓		✓	✓	✓	✓	✓	✓	✓	5	5	✓
Agenda Partner (30 minute presentation) £15,000		✓	✓	✓				✓	✓	3	3	✓
Agenda Partner (panel) £11,500								✓	✓	2	2	✓
Tech Spotlight Partner £7,500		✓						✓	✓	2		✓
Innovation Partner £7,500		✓						✓	✓	2		✓
Exhibitor £5,000								✓	✓	2		✓
Networking Partner £3,500									✓	2		✓

For more information contact:

Denvor Oorloff, Commercial Manager, T: +44 (0) 208 191 8810 E: denvor@frontlinegenomics.com

*where attendee has given permission